Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CIK cells for hematological malignancies after chemotherapy or hematopoietic stem cell transplantation
ChiCTR-TNRC-11001806Phase 2Completed
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Dec 2011
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous cytokine-induced killer cells in hematopoietic malignancies, lymphoma, leukemia and 3 more (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoints: Immune index, Disease-free survival and 1 more. Started Dec 2011; status: completed.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
hematopoietic malignancieslymphomaleukemiamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR-TNRC-11001806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNRC-11001806.